Friday, November 20, 2026

TherapeuticsMD Stock Bearish Momentum With A 9% Slide So Far Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

TherapeuticsMD Stock Bearish Momentum With A 9% Slide So Far Today

(VIANEWS) - Shares of TherapeuticsMD (NASDAQ: TXMD) fell 9.44% to $4.03 at 11:56 EST on Wednesday, following the last session's upward trend. NASDAQ is sliding 0.43% to $13,219.74, following the last session's upward trend. This seems, so far, a somewhat down trend trading session today.

TherapeuticsMD's last close was $4.45, 61.93% below its 52-week high of $11.69.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $1.99.

PE Ratio

TherapeuticsMD has a trailing twelve months price to earnings ratio of 2.03. Meaning, the purchaser of the share is investing $2.03 for every dollar of annual earnings.

Volatility

TherapeuticsMD's last week, last month's, and last quarter's current intraday variation average was 2.39%, 0.79%, and 3.46%.

TherapeuticsMD's highest amplitude of average volatility was 3.00% (last week), 3.28% (last month), and 3.46% (last quarter).

Yearly Top and Bottom Value

TherapeuticsMD's stock is valued at $4.03 at 11:56 EST, way under its 52-week high of $11.69 and way higher than its 52-week low of $3.25.

Earnings Before Interest, Taxes, Depreciation, and Amortization

TherapeuticsMD's EBITDA is 0.2.

More news about TherapeuticsMD (TXMD).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 7 Jun 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.